RTMP's COPY
9703606-5.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61K 31/40 — A2

(11) International Publication Number: WO 96/24348

(43) International Publication Date: 15 August 1996 (15.08.96)

(21) International Application Number: PCT/EP96/00498

(22) International Filing Date: 7 February 1996 (07.02.96)

(30) Priority Data:
195 03 995.5 — 8 February 1995 (08.02.95) — DE
08/483,635 — 7 June 1995 (07.06.95) — US

(71) Applicant *(for all designated States except US)*: BOEHRINGER MANNHEIM PHARMACEUTICALS CORPORATION [US/US]; SmithKline Beecham Corporation, Limited Partnership No. 1, 101 Orchard Ridge Drive, Gaithersburg, MD 20878 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: LUKAS-LASKEY, Mary, Ann [US/US]; 1019 Great Springs Road, Rosemont, PA 19010 (US). RUFFOLO, Robert, Jr. [US/US]; 725 Pughtown Road, Spring City, PA 19475 (US). SHUSTERMAN, Neil [DE/DE]; 451 Ballytore Road, Wynnewood, PA 19096 (DE). SPONER, Gisbert [DE/DE]; Lessingstrasse 13, D-69514 Laudenbach (DE). STREIN, Klaus [DE/DE]; Eichenstrasse 45, D-69503 Hemsbach (DE).

(74) Agent: WEBER, Manfred; Boehringer Mannheim GmbH, Patent Dept., D-68298 Mannheim (DE).


(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ, BY, KG, KZ, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: USE OF CARBAZOLE COMPOUNDS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE

(57) Abstract

A method of treatment using a compound of formula (I), wherein R_1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl; R_2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl; R_3 is hydrogen or lower alkyl of up to 6 carbon atoms; R_4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R_4 together with R_5 can represent $-CH_2-O-$; X is a valency bond, $-CH_2$, oxygen or sulfur; Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl; R_5 and R_6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a $-CONH_2-$ group, lower alkoxy of up to 6 carbon atoms, benzyloxy, lower alkylthio of up to 6 carbon atoms, lower alkysulphonyl of up to 6 carbon atoms and lower alkylsulphonyl of up to 6 carbon atoms; or R_5 and R_6 together represent methylenedioxy; or a pharmaceutically acceptable salt thereof, preferably carvedilol, alone or in conjunction with one or more other therapeutic agents, said agents being selected from the group consisting of ACE inhibitors, diuretics, and cardiac glycosides for decreasing mortality resulting from congestive heart failure (CHF) in mammals, particularly humans.



(I)